TEST - Company Roster
Corporate Member Roster (All)
Abbott Diabetes Care
Through a steadfast commitment to research, technology and state-of-the-art manufacturing, Abbott has developed a diverse portfolio of breakthrough diabetes products designed to meet the needs of each unique patient. Our innovative product development program is responsible for several groundbreaking technologies. Keep looking to our dedicated teams for the next generation of highly innovative and effective glucose monitoring products. We aim to set the standard for helping patients and healthcare providers to potentially achieve the best health outcomes.
AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.
ACADIA Pharmaceuticals, Inc.
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at acadia.com and follow us on LinkedIn and X.
ALK Inc
As a world leader in allergy immunotherapy, ALK works to improve quality of life for the many allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication, by developing products that provide long-lasting relief. The company has approximately 2,000 employees, with subsidiaries, production facilities and distributors worldwide. ALK is headquartered in Denmark and listed on NASDAQ Copenhagen (OMX: ALK B).
Alkermes, Inc.
Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression.
Alnylam Pharmaceuticals
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.
Amarin Pharma, Inc.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product availably by prescription.
Amgen, Inc.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, with a presence in approximately 100 countries and regions worldwide. Our innovative medicines have reached millions of people in the fight against serious illnesses, with a focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.
Argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Artia Solutions
Artia Solutions provides drug manufacturers with the resources, guidance, and support needed to successfully launch or manage their medical or pharmacy benefit products within the Medicaid and Medicaid Managed Care marketplaces. Our vision is to ultimately enhance the lives of patients by creating access to essential medications.
Arvinas
Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins. For people living with cancers and other difficult-to-treat diseases, our approach has the potential to be transformative. Our proprietary PROTACs, or proteolysis-targeting chimeras, are designed to work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Ascendis Pharma
Ascendis Pharma is applying its innovative TransConTM technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, rare disease endocrinology product candidates in clinical development. We have also established oncology as our second therapeutic area of focus.
Astellas Pharma US, Inc.
Launched in April 2005, Astellas was formed by the historical merger of Japan’s third and fifth largest pharmaceutical companies- Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Created from a partnership of two respected, leading global companies, Astellas is built on a strategic platform focused in select therapeutic areas: Cardiology, Dermatology, Immunology, Infectious Disease, Oncology and Urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients and partners. Key strategic products include: Prograf, VESIcare, Lexiscan, Adenoscan, Protopic, Amevive, AmBisome and Mycamine.
AstraZeneca, L.P.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Avadel
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Avidity Biosciences
Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution.
Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
Bayer
“Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.”
BeOne Medicines USA, Inc.
BeOne Medicines USA, Inc., formerly known as BeiGene USA, Inc., is a US subsidiary of a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. To learn more, please visit https://beonemedicines.us/
Braeburn Pharmaceutical
Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the management of opioid use disorder (OUD) by partnering with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential. If applicable: Visit https://braeburnrx.com to learn more.
Connect with Braeburn on LinkedIn at https://linkedin.com/company/Braeburn
Calliditas NA Enterprise Inc
Calliditas Therapeutics is a specialty pharmaceutical company headquartered in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a two-step unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US.
Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. We deliver comprehensive strategies to engage globally and locally through one partner. From clinical to commercial and every point between, we strive for accelerated speed to market and better outcomes. Cencora has a proven history of partnership, bringing complex and transformative therapies to market. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures.
Center for Innovation & Value Research
The Innovation and Value Initiative (IVI) is an independent, nonprofit research organization with a mission to advance the science, practice, and use of patient-centered health technology assessment (HTA) to support decisions that make healthcare more meaningful and equitable. We envision a learning healthcare system supported by patient-centered HTA that is focused on high-quality, efficient, and equitable care for all people and communities.
Chiesi USA
Chiesi USA is a specialty pharmaceutical company committed to research, development, production and commercialization of innovative products in the areas of cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. Our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Chiesi USA, as they strive to build their company, their family and their community.
Coherus Oncology
Coherus Oncology is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Coherus was founded in 2010 to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.
CSL Behring
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited headquartered in Melbourne, Australia, employs more than 25,000 people worldwide, and delivers its life-saving therapies to people in more than 100 countries.
CVS Health
CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of March 31, 2025, the Company had more than 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics, a leading pharmacy benefits manager with approximately 88 million plan members, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Cytokinetics
We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function, like heart failure, hypertrophic cardiomyopathies (HCM), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). By focusing on impacting the mechanics of muscle with investigational medicines that may improve strength, power, or performance, we aspire to develop new treatment options that may dramatically improve the lives and functionality of people living with debilitating diseases.We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
Daiichi Sankyo, Inc.
At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication. We rely on reason, ingenuity, perseverance and empathy to make bold strides in oncology. Our success comes from experts in collaboration: our people, scientists, health care providers, advocates – and patients themselves. Every partner on our journey, each passionately bringing their own skills and insights to bear, is essential. We seek out the patient voice and incorporate it into what we do each day, so that our continuous investment in cancer treatment research can make the biggest possible difference.
Dexcom Inc.
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Eisai, Inc.
Satisfying diverse healthcare needs around the world ~ Around the world there are still many diseases for which no effective treatments exist and many patients who do not have adequate access to the medicines they need. As a global pharmaceutical company addressing these unmet medical needs, Eisai is committed to making contributions to better healthcare for patients and their families around the world through its business activities.
Elevar Therapeutics
Elevar Therapeutics, Inc., a fully owned subsidiary of HLB Group, is a fully integrated biopharmaceutical company built on the promise of elevating treatment outcomes for patients who have limited or inadequate therapeutic options. With expertise rooted in oncology, Elevar is focused on identifying and developing promising medicines for complex yet under-treated health conditions. Elevar’s lead proprietary drug candidate is rivoceranib.
Emalex Biosciences
Emalex is unceasing in its pursuit to improve the lives of people living with central nervous system (CNS) disorders through meaningful scientific breakthroughs
embecta
embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.
Emerging Therapy Solutions
Emerging Therapy Solutions® (ETS) helps healthcare payers – including reinsurance and stop-loss payers, health plans and self-funded employers – manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies.
Exelixis, Inc.
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. Exelixis was founded and incorporated in 1994 and we are based in South San Francisco, California. Exelixis is dedicated to improving the care of, and outcomes for patients with cancer.
Express Scripts by Evernorth
Express Scripts, the pharmacy benefits management (PBM) business of Evernorth Health Services has a simple mission: To improve clinical outcomes and lower the cost of prescription drugs for the one in three Americans we serve. Driven and proactive, our dedicated teams leverage data analytics and insights to anticipate and address tough challenges while reducing plan and member costs. We deliver the care and attention members need—and the simpler health care experience they deserve. To learn more, please visit our website.
Family Heart Foundation
The mission of the Family Heart Foundation is to save generations of families from heart disease through timely identification and improved care of familial hypercholesterolemia and elevated lipoprotein(a).
The Family Heart Foundation is pioneering research, advocacy, and education to help prevent heart attacks and strokes caused by elevated lipoprotein(a), Lp(a), and familial hypercholesterolemia, FH, two inherited disorders that have an impact across generations. We play a critical role in driving change and empowering families to navigate their own health.
GE Healthcare
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Genentech Inc.
Genentech, Inc. is a leading biotechnology company focusing on the discovery, development, manufacture, and marketing of pharmaceuticals for significant, unmet medical needs. Genentech’s managed care specialists are committed to enhancing the quality and delivery of patient care by working with managed care organizations to find effective solutions to health care issues.
Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
GSK
GlaxoSmithKline (GSK), one of the world’s leading research-based health care companies, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medications and health-related products. GSK’s people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to the health care providers who serve them.
Health Delegates
Health Delegates is a strategic health care advisory and clinical services firm specializing in pharmacy benefit optimization. We partner with health plans, PBMs, and employers to deliver customized formulary management, rebate contracting, and clinical oversight solutions that drive down drug spend while improving patient outcomes.
Illumina, Inc.
Our mission is to improve human health by unlocking the power of genome.
Incyte Corporation
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. The company’s first commercial product, Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor, is approved by the FDA to treat two rare blood disorders--first approved in November 2011 Jakafi received a subsequent U.S. approval in December 2014.
Inovalon
Inovalon is a leading provider of cloud-based SaaS solutions empowering data-driven healthcare. The Inovalon ONE® Platform brings together national-scale connectivity, real-time primary source data access, and advanced analytics to enable improved clinical outcomes and economics across the healthcare ecosystem. For more information, visit www.inovalon.com
Ipsen Biopharmaceuticals
Ipsen is a leading biopharmaceutical group dedicated to improving lives through innovative medicines in oncology , neuroscience and rare diseases. Ipsen’s mission, “innovation for patient care”, highlights the Group’s determination to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. As well as our dedication to improving the lives of patients, Ipsen is also firmly committed to protecting the environment and to supporting civil society and the communities in which we operate. The Group is pledged to promote ethical, responsible and transparent professional practices.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
Johnson & Johnson Health Care Companies
Johnson & Johnson Health Care Companies are committed to creating measurable value for our managed markets customer through a dedicated focus on meeting your needs. In doing so, we will draw on our wide range of innovative products and services. We can work together to improve your clinical and business outcomes.
Kaleo
Kaléo is a fully integrated pharmaceutical company dedicated to inventing, manufacturing and commercializing life-transforming products that empower patients with certain serious and life-threatening medical conditions to live fuller, bolder lives. We believe patients and caregivers are the experts on how medical conditions impact their lives, and so we include them as an integral part of our development process and consider their needs foremost. Kaléo’s innovative auto-injection technologies are protected by an extensive intellectual property portfolio of more than 200 issued patents. Kaléo is headquartered in Richmond, Virginia in the United States. For more information, visit www.kaleo.com.
Kiniksa Pharmaceuticals
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation.
KlearTrust
KlearTrust engages life science companies, payers, and providers with the only comprehensive, independent, digital solution to operationalize even the most complex value-based agreements. From contract and program design to real-time clinical performance monitoring and stakeholder alerts to risk mitigation and underwriting, KlearTrust is the trusted platform for realizing the promise of value-based care.
Kroger Prescription Plans
Kroger Prescription Plans has provided comprehensive Pharmacy Benefits Management services since 1993. We combine transparency and highly competitive pricing to drive lower costs for clients and their members, while at the same time delivering exceptional customer service. Our plans are flexible and adaptable. Kroger Prescription Plans is focused on improving the health & wellness of our customers. We are committed to advancing health, reducing costs and improving the efficacy of any client’s health strategy.
LEO Pharma
LEO Pharma Inc. is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology. LEO Pharma products have been available in the U.S. since 1994, and the company opened the U.S. affiliate in January 2010. The company's U.S. offices are located in Madison, N.J. LEO Pharma has a 100+ year history as a specialty pharmaceutical company, committed to the discovery and development of novel drugs for patients; markets products in 100+ countries worldwide; employs 6,000 dedicated colleagues operating across 61 countries, and remains wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark, outside Copenhagen.
Lilly USA, LLC
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquarted in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.
MedImpact Healthcare Systems, Inc.
MedImpact is the PBM that puts clients and consumers first. For 30 years, it has had a single mission: To make pharmacy benefits affordable, understandable, and transparent. Today, MedImpact’s team and technology serve many large employers and plans, and more than 55 million consumers in the US and around the world. Learn more at medimpact.com or follow us on Twitter @MedImpact.
Merck & Co., Inc.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work wtih customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
Milliman
Independent for over 70 years, Milliman delivers market-leading services and solutions to clients worldwide. With no agenda, other than getting it right.Through a team of professionals ranging from actuaries to clinicians, technology specialists to plan administrators, we offer unparalleled expertise in employee benefits, investment consulting, healthcare, life insurance and financial services, and property and casualty insurance.
Moderna Inc.
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Neurelis
Neurelis is a unique company focused on therapies for disorders involving the central nervous system. Our company is built on a foundation of passion and progress. This passion fuels our drive to successfully deliver innovative therapies that have the potential to change the lives of patients, caregivers, and healthcare providers. Neurelis is a neuroscience-based specialty pharmaceutical company dedicated to enhancing therapeutic benefit and addressing unmet needs in patient care.
Novo Nordisk, Inc.
Novo Nordisk is a global healthcare company committed to discovering and developing innovative medicines to help people with serious chronic conditions and rare diseases lead longer, healthier lives. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure life-threatening diseases.
OncoHealth
OncoHealth is dedicated to helping health plans, employers, oncologists, and patients navigate the physical, mental, and financial complexities of cancer. Focused 100% on oncology, OncoHealth’s market-leading software and services platform combines oncology value management services with virtual cancer care to ensure people with cancer are getting the most appropriate treatment and supported through the duration of their treatment with services including 24/7 oncology nursing, mental health, nutrition, and resource navigation. To learn more, visit www.oncohealth.us.
Organon USA Inc.
Organon Pharmaceuticals USA Inc. is the U.S. affiliate of N.V. Organon, a renowned international ethical pharmaceutical company. Organon – with shared head offices in Roseland, N.J., USA and Oss, The Netherlands – creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its cores therapeutic fields: reproductive medicine, psychiatry and anaesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. Akzo Nobel is an international company active in the areas of pharmaceuticals, coatings and chemicals with approximately 61,000 employees and operations in over 80 countries.
Otsuka Pharmaceutical Development & Commercialization Inc.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI).
Outcomes
Outcomes® unites technology and clinical relationships through a connected healthcare network to drive better outcomes. As a leading patient-centric technology business, we unite pharmacies, payers, and pharmaceutical companies through patient engagement solutions, tailored tools for the future pharmacy, and advanced workflow optimization. Our comprehensive offerings benefit a nationwide network of 48,000 community, chain, and grocery pharmacies, and more than 70 million patients.
Pearldiver Technologies
PearlDiver Technologies "PearlDiver" is a healthcare research organization that offers customizable research services at a controlled cost. PearlDiver's proprietary Bellwether Research Software ™ is delivered as a subscription as a service. Bellwether™ functions to provide a user-friendly user interface that allows researchers to point and click to establish medical cohorts specific to the subscriber's needs. The interface solely interacts with PearlDiver's Mariner Database™ to provide fast, accurate, customizable research, with access to one of the largest healthcare databases in the world with over 71 billion longitudinally integrated, HIPAA-compliant patient records amongst over 160 million unique patient lives. The PearlDiver Mariner Database ™ offers hospitals, medical industry professionals, medical device, pharmaceutical executives, analysts, and regulatory agencies critical insights and actionable information across all payer types. The Mariner Database™ draws from multiple payer types of a patient's healthcare experience(s). These payer types include commercial health plans, government plans such as Medicare and Medicaid, employer-sponsored plans, worker's compensation, and cash payments made by the patient.
PerformRx
PerformRx is a clinically focused, full-service pharmacy benefit manager with more than 20 years of experience serving Medicaid, Medicare, and commercial markets. Founded in 1999 to challenge the profit-centric PBM model, PerformRx was established with a singular mission: to improve the health and well-being of its members through personalized, outcomes-driven pharmacy care. As a clinician-led and nationally accredited organization, PerformRx partners closely with health plans, providers, and pharmacy networks to deliver data-informed strategies that promote access, close care gaps, and optimize medication use. The company also operates its own URAC-accredited specialty pharmacy, PerformSpecialty, offering seamless integration and continuity of care for complex conditions.
Pfizer Inc.
As one of the world’s leading healthcare companies, Pfizer has developed and brought to market medicines for humans and animals for over 150 years. Our portfolio includes more category-leading medicines than any other company – treatments that are helping countless people everyday to ease arthritis and nerve pain, manage depression, fight diabetes and cancer and control hypertension. Our portfolio of innovative medicines currently includes treatments for more than a dozen disease areas and we are targeting unmet medical needs through state-of-the-art research and development. We know that healthcare is more than a business—it’s a mission-and our products can only help people if they can get them. That’s why we are deeply committed to enhancing access to high-quality healthcare. This year, through innovative partnership programs, Pfizer is giving product donations for patients in need around the world and building the infrastructure necessary to ensure that the medicines get to those who need it most.
Pharmaceutical Strategies Group
Pharmaceutical Strategies Group (PSG), an EPIC company, advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG’s innovative solutions, driven by industry-leading business strategies and proprietary data and analytics platform, Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through cutting-edge technology and unparalleled expertise to realize significant drug cost savings for clients every year. As a fiercely independent organization, our mission is to act solely in the best interest of our clients to help maximize their pharmacy benefit investment and enhance member outcomes.
Pharmacosmos Therapeutics, Inc.
Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anaemia. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs, with a focus on iron metabolism and blood-related disorders. Founded in 1965 and headquartered in Denmark, our team is made up of more than 700 specialists across the UK, Ireland, the Nordics, Germany, the USA, and China
Pharvaris GmbH
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both prophylactically and on-demand.
Deucrictibant is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist currently in clinical development. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable prophylactic treatment, and an immediate-release capsule to enable on-demand treatment.
Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life changing medicines. Our global offerings include: Commercial Consulting, HEOR, Market Access Marketing, Medical Communications, Advertising, Branding, & PR, Investor Relations & External Communications, and Data & Product solutions. Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights to deliver new pathways for life-changing medicines.
Prime Therapeutics LLC
Prime Therapeutics is a trusted, truly transparent pharmacy solutions partner delivering savings, simplicity and support to our customers and members. Our 7,000+ dedicated employees are committed to challenging norms and curating innovative pharmacy solutions that simplify the complex and provide exceptional experiences for millions of people across the nation.
PTC Therapeutics
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.
Regeneron
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Revolution Medicines
Revolution Medicines is a clinical-stage biotechnology company, and our mission is to revolutionize treatment for patients with RAS-addicted cancers through the discovery, development and delivery of innovative, targeted medicines.
Rx Savings Solutions
Rx Savings Solutions, part of McKesson Corporation, works on behalf of health plans and self-insured employers to help their members reduce out-of-pocket prescription costs and the plan’s pharmacy spend. The solution layers on top of an existing pharmacy benefit and analyzes individual claims to identify and present cost-saving alternatives to each member. Whenever savings opportunities are found, members are proactively notified through preferred communication channels. They engage with the solution through a personal online portal, mobile app and live, concierge member support provided by certified pharmacy technicians. Rx Savings Solutions currently serves 18 million members nationwide.
Samsung Bioepis United States
Samsung Bioepis is a biopharmaceutical company dedicated to unlocking the potential of biosimilar medicines and transforming the way biologic therapies are brought to patients. Our mission is reflected in our name, bio-epis; literally meaning life (“bio”) and science (“episteme”) in Greek. We want to enhance the lives of patients through our pioneering and innovative use of science and technology.
Sandoz
At Sandoz, we specialize in the development of generic and biosimilar medicines. That means we develop more affordable versions of high-quality medicines once their key patents have expired. For us, pioneering access for patients means going new ways in how we develop new products in line with patient needs, how we produce cutting-edge medicines at prices people can afford, and how we get the medicines to the patients who need them. As the leading supplier of such medicines – which account for around 80% of medicines worldwide – we make access to high-quality medicines more affordable.
Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Soleno Therapeutics
Soleno Therapeutics, Inc. (Soleno) is dedicated to the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead product, VYKAT™ XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in individuals aged 4 and older with Prader-Willi syndrome (PWS). For more information, please visit soleno.life.
SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
Sumitomo Pharma Co.,Ltd.
Driven by a pursuit of innovation on behalf of the patients we serve, Sumitomo Pharma America, Inc. (SMPA) delivers needed products and accelerates drug development in key areas of unique and unmet medical need for people worldwide. Across multiple therapeutic areas and clinical research programs, including oncology, women’s health, urology, rare disease, neurology & psychiatry and cell & gene therapies, we operate with scientific rigor, compassion and determination to bring needed therapies to patients sooner, and to deliver better experiences for patients and caregivers on the things that matter most to them.
Supernus Pharmaceuticals Inc.
With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. We are developing several product candidates in neurology and psychiatry to address unmet medical needs and opportunities in epilepsy, attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Syndax Pharmaceuticals
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.
Taiho Oncology, Inc.
Taiho Oncology, Inc. a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho’s oral oncology pipeline consists of both novel antimetabolic agents and selectively targeted agents.
Takeda Pharmaceuticals America, Inc.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.
Teva Pharmaceuticals
Teva Pharmaceuticals has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,600 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products.
©2023 Teva Neuroscience, Inc. NPS-40577 March 2023
TOLMAR Inc.
TOLMAR is a fully integrated company focused on the development, approval, and commercialization of specialty pharmaceutical products, including a line of generic dermatology products where TOLMAR is an established leader, and specialty injectable oncology products. Invention, development, and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer has established TOLMAR as a leader dedicated to the urology community, providers, and patients. TOLMAR has 24 FDA-approved products.
Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
UCB
UCB's ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders - putting patients at the center of our world. We are Inspired by Patients. Driven By Science. UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions - so that they and their carers can get on with their lives.
United Healthcare
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. We are 340,000 colleagues in two distinct and complementary businesses working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences. We work with governments, employers, partners and providers to care for 147 million people and share a vision of a value-based system of care that provides compassionate and equitable care. At UnitedHealth Group, our mission calls us, our values guide us and our diverse culture connects us as we seek to improve care for the consumers we are privileged to serve and their communities.
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients.
Viatris
Viatris is a global healthcare company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce of ~45,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance. Our global portfolio includes best-in-class, iconic brand-name products as well as global key brands; generics, including branded and complex generics; biosimilars; and over-the-counter offerings across a wide range of therapeutic areas. We are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.